|
gptkbp:instance_of
|
gptkb:physicist
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:PX-770
gptkb:BRAF_V600_E_mutation
gptkb:B-Raf
gptkb:Lenvima
|
|
gptkbp:antagonist
|
selective inhibitor
|
|
gptkbp:associated_with
|
gptkb:healthcare_organization
|
|
gptkbp:clinical_trial
|
target for cancer therapy
|
|
gptkbp:code
|
B-Raf protein
|
|
gptkbp:discovered_by
|
David L. Long
|
|
gptkbp:established
|
gptkb:vemurafenib
gptkb:dabrafenib
encorafenib
|
|
gptkbp:function
|
serine/threonine kinase
|
|
gptkbp:genetic_diversity
|
10-20% in thyroid cancer
40-60% in melanoma
5-15% in colorectal cancer
V600 D
V600 E
V600 K
V600 R
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BRAF
|
|
gptkbp:interacts_with
|
gptkb:Raf-1
gptkb:C-Raf
ME K1
ME K2
|
|
gptkbp:is_a_route_for
|
MAPK/ ERK pathway
|
|
gptkbp:is_involved_in
|
apoptosis
cell differentiation
cell proliferation
|
|
gptkbp:is_recognized_by
|
gptkb:1990
|
|
gptkbp:located_in
|
chromosome 7
|
|
gptkbp:nutritional_value
|
RAF kinase family
|
|
gptkbp:research_focus
|
cancer genetics
|
|
gptkbp:role
|
cell signaling
|
|
gptkbp:social_responsibility
|
gptkb:chronic_myeloid_leukemia
gptkb:healthcare_organization
gptkb:historical_figure
gptkb:cervical_cancer
gptkb:Wilms_tumor
gptkb:neuroblastoma
ovarian cancer
endometrial cancer
esophageal cancer
bladder cancer
head and neck cancer
Langerhans cell histiocytosis
hairy cell leukemia
|